Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.
Sponsor:
NovartisPhase:
Phase 1/2
Contacts:
Novartis Pharmaceuticalsnovartis.email@novartis.com
1-888-669-6682
Government Study Link:
NCT06881823 - Click here to see study onClinicalTrials.gov
Help us improve your experience